Related Experiment Video
Updated: Jun 18, 2026
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
beta1 integrin targeting to enhance radiation therapy.
Jin-Min Nam1, Yoonsun Chung, Howard C Hsu
1Life Sciences Division, Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, California 94143-1708, USA.
International Journal of Radiation Biology
|November 10, 2009
Summary
Beta1 integrin signaling promotes cancer cell resistance to radiation therapy. Targeting these pathways may improve breast cancer treatment outcomes by enhancing radiosensitivity.
Area of Science:
- Oncology
- Cell Biology
- Radiotherapy Research
Background:
- Cell adhesion to extracellular matrix (ECM) proteins involves integrins.
- Integrin signaling influences cancer cell radiation sensitivity and resistance.
- Beta1 integrin signaling is linked to cancer progression, metastasis, and radioresistance.
Purpose of the Study:
- To review integrin targeting strategies in radiation therapy.
- To highlight updated findings on beta1 integrin signaling post-ionizing radiation (IR).
- To identify potential therapeutic targets for breast cancer radiation therapy.
Main Methods:
- Review of in vitro experimental models.
- Review of in vivo experimental models.
- Analysis of beta1 integrin-mediated signaling pathways.
Main Results:
- Beta1 integrin signaling pathways are activated by ionizing radiation.
- These pathways contribute to radiation resistance in cancer cells.
- Experimental models demonstrate the role of beta1 integrin in modulating radiosensitivity.
Conclusions:
- Integrin targeting is a viable strategy in radiation therapy.
- Beta1 integrin signaling pathways represent promising therapeutic targets.
- Targeting beta1 integrin may enhance the efficacy of radiation therapy for breast cancer.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.